Articles

An interview with Nicola Mutch
News

An interview with Nicola Mutch

We met with Nicola Mutch, president elect of the ISTH SCC, during the 9th ICTHIC in Bergamo.

Read More
Arterial thromboembolism can also be the first clinical manifestation of a neoplasm
Solid Tumors

Arterial thromboembolism can also be the first clinical manifestation of a neoplasm

Several studies showed that venous thrombosis can be the first clinical manifestation of an occult neoplasm.

Read More
Anticoagulant treatment in patients with thrombocytopenia and cancer-associated thrombosis
Anticoagulation Drugs

Anticoagulant treatment in patients with thrombocytopenia and cancer-associated thrombosis

One of the most complex situations in the treatment of cancer-associated thrombosis is represented by oncological patients with thrombocytopenia...

Read More
Rapping about new anticoagulants for CAT at ICTHIC 2018
Clinical

Rapping about new anticoagulants for CAT at ICTHIC 2018

Cancer patients are four or five times as likely to develop venous thromboembolism (VTE): not only does the disease increase the incidence but so do treatments such as chemotherapy and radiation. Drugs which can treat it and prevent recurrences are therefore an important part of oncology strategies.

Read More
Hemostatic proteins and cancer biology: news from the research groups
News

Hemostatic proteins and cancer biology: news from the research groups

The expression of hemostatic proteins in cancer and their role in cancer biology is one of the themes that have been discussed during ICTHIC 2018.

Read More
Clinical challenges in the management of cancer patients with hemostatic disorders
News

Clinical challenges in the management of cancer patients with hemostatic disorders

The management of cancer patients with hemostatic disorders (thrombosis and/or bleeding) faces many clinical challenges.

Read More
The conundrum of anti-angiogenesis in cancer
News

The conundrum of anti-angiogenesis in cancer

Anti-angiogenesis in cancer is something of a conundrum where the unexpected is to be expected.

Read More
Debate: Are new anticoagulants a safe and reasonable alternative to low molecular weight heparins?
News

Debate: Are new anticoagulants a safe and reasonable alternative to low molecular weight heparins?

During the 9th ICTHIC Dr. Buller and Dr. Noble were to challenged discuss their point of view about whether the new anticoagulants are a safe and reasonable alternative to low molecular weight heparins.

Read More
Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer
Epidemiology

Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer

Morbidity, Mortality and Costs Associated with Venous Thromboembolism in Hospitalized Patients with Cancer

Read More
CAT Studies
Trial Update

CAT Studies

A selection of the clinical trials about CAT.

Read More

Page 1 of 4